For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
11
views
0
references
 Top references
cited by
17
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      360
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Indacaterol/glycopyrronium (IND/GLY) is a once-daily inhaled fixed-dose combination of indacaterol (IND), a long-acting β2-adrenergic agonist (LABA), and glycopyrronium (GLY), a long-acting muscarinic antagonist (LAMA) for use as maintenance treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults.

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): Respir Med
          Title: Respiratory medicine
          Publisher: Elsevier BV
          ISSN (Electronic): 1532-3064
          ISSN (Print): 0954-6111
          Publication date (Electronic): Dec 2014
          Volume: 108
          Issue: 12
          Affiliations
          [1 ] Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Aberdeen AB25 2ZD, UK.
          [2 ] Primary Care Franchise, Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland.
          [3 ] Novartis Pharma AB, Box 1150, TÄBY, Stockholm S-183 79, Sweden. Electronic address: madlaina.costa-scharplatz@novartis.com.
          [4 ] IMS Health Economics and Outcomes Research, 210 Pentonville Road, London N1 9JY, UK.
          [5 ] Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden.
          Article
          Publisher Item ID: S0954-6111(14)00326-6
          DOI: 10.1016/j.rmed.2014.09.015
          PubMed ID: 25307414
          SO-VID: c2fd6045-bfb1-41c6-8c1a-42931f2181b3
          History

          Keywords: COPD,Cost-effectiveness,Cost-minimisation,Costs,Economic evaluation
          Data availability:
          Keywords: COPD, Cost-effectiveness, Cost-minimisation, Costs, Economic evaluation

          Comments

          Comment on this article

          scite_

          Similar content360

          See all similar

          Cited by17

          See all cited by